NASDAQ:DCPH Deciphera Pharmaceuticals (DCPH) Stock Price, News & Analysis → The Military's $700M 'AI Software Bullet' (From Behind the Markets) (Ad) Free DCPH Stock Alerts $25.59 0.00 (0.00%) (As of 06/11/2024) Add Compare Share Share Today's Range$25.59▼$25.5950-Day Range$14.18▼$25.5952-Week Range$9.90▼$25.61VolumeN/AAverage Volume1.29 million shsMarket Capitalization$2.21 billionP/E RatioN/ADividend YieldN/APrice Target$24.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Deciphera Pharmaceuticals alerts: Email Address Deciphera Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.30 Rating ScoreUpside/Downside5.5% Downside$24.17 Price TargetShort InterestHealthy5.71% of Float Sold ShortDividend StrengthN/ASustainability-1.60Upright™ Environmental ScoreNews Sentiment1.32Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.15) to ($1.77) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.32 out of 5 starsMedical Sector294th out of 913 stocksPharmaceutical Preparations Industry130th out of 429 stocks 2.2 Analyst's Opinion Consensus RatingDeciphera Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on 3 buy ratings, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageDeciphera Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Deciphera Pharmaceuticals' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.71% of the float of Deciphera Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverDeciphera Pharmaceuticals has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Deciphera Pharmaceuticals has recently decreased by 19.13%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldDeciphera Pharmaceuticals does not currently pay a dividend.Dividend GrowthDeciphera Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDeciphera Pharmaceuticals has received a 50.76% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Ripretinib", "Preclinical research services for physical health", and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for Deciphera Pharmaceuticals is -1.60. Previous Next 3.0 News and Social Media Coverage News SentimentDeciphera Pharmaceuticals has a news sentiment score of 1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Deciphera Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 5 people have searched for DCPH on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Deciphera Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.67% of the stock of Deciphera Pharmaceuticals is held by insiders.Percentage Held by Institutions70.96% of the stock of Deciphera Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Deciphera Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Deciphera Pharmaceuticals are expected to grow in the coming year, from ($2.15) to ($1.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Deciphera Pharmaceuticals is -11.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Deciphera Pharmaceuticals is -11.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDeciphera Pharmaceuticals has a P/B Ratio of 5.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Deciphera Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Congress shifting their stocks in a frenzy? And why are they all piling into ONE unique corner of the market…Click here for the details About Deciphera Pharmaceuticals Stock (NASDAQ:DCPH)Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.Read More DCPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DCPH Stock News HeadlinesJune 3, 2024 | businesswire.comDeciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The LancetMay 22, 2024 | msn.comDeciphera Pharmaceuticals ticks higher as HSR waiting period for ONO sale expiresMay 16, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Deciphera Pharmaceuticals (DCPH), Atara Biotherapeutics (ATRA) and Nkarta (NKTX)May 14, 2024 | markets.businessinsider.comDeciphera Pharmaceuticals: Hold Rating Amid Acquisition and Concerns Over Qinlock SalesMay 10, 2024 | investorplace.comDCPH Stock Earnings: Deciphera Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024May 2, 2024 | stockhouse.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MCBC, DCPH, HTLF, TBNKMay 1, 2024 | businesswire.comDECIPHERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Deciphera Pharmaceuticals, Inc. - DCPHMay 1, 2024 | msn.comBarclays Upgrades Deciphera Pharmaceuticals (DCPH)April 30, 2024 | msn.comJefferies Downgrades Deciphera Pharmaceuticals (DCPH)April 30, 2024 | markets.businessinsider.comDeep Dive Into Deciphera Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)April 30, 2024 | msn.comJonesTrading Downgrades Deciphera Pharmaceuticals (DCPH)April 30, 2024 | finance.yahoo.comONO Enters into a Definitive Agreement to Acquire Deciphera PharmaceuticalsApril 30, 2024 | reuters.comJapan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansionApril 29, 2024 | prnewswire.comINVESTIGATION: The M&A Class Action Firm Announces An Investigation of Deciphera Pharmaceuticals, Inc. - DCPHApril 29, 2024 | msn.comDeciphera to be acquired by Japanese drug firm for $2.4 billionApril 29, 2024 | finance.yahoo.comUpdate: Deciphera Pharmaceuticals to Be Acquired by ONO Pharmaceutical in $2.4 Billion DealApril 29, 2024 | finance.yahoo.comDeciphera Pharmaceuticals Is Being Acquired and the Stock Soars 72%April 29, 2024 | investorplace.comWhy Is Deciphera Pharmaceuticals (DCPH) Stock Up 72% Today?April 29, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Deciphera Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with ONO Pharmaceutical Co.April 29, 2024 | barrons.comDeciphera Pharmaceuticals Is Being Acquired and the Stock Soars 71%April 29, 2024 | businesswire.comDCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Deciphera Pharmaceuticals, Inc. Is Fair to ShareholdersApril 29, 2024 | reuters.comJapan's ONO Pharmaceutical to buy Deciphera for $2.4 billionApril 29, 2024 | businesswire.comDeciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 BillionApril 27, 2024 | nasdaq.comDCPH Makes Notable Cross Below Critical Moving AverageApril 26, 2024 | seekingalpha.comDiving Into Deciphera PharmaceuticalsSee More Headlines Receive DCPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Deciphera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today6/17/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DCPH CUSIPN/A CIK1654151 Webwww.deciphera.com Phone(781) 209-6400FaxN/AEmployees355Year FoundedN/APrice Target and Rating Average Stock Price Target$24.17 High Stock Price Target$30.00 Low Stock Price Target$16.00 Potential Upside/Downside-5.5%Consensus RatingHold Rating Score (0-4)2.30 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-194,940,000.00 Net Margins-108.86% Pretax Margin-108.62% Return on Equity-52.42% Return on Assets-40.05% Debt Debt-to-Equity RatioN/A Current Ratio4.19 Quick Ratio3.94 Sales & Book Value Annual Sales$174.91 million Price / Sales12.65 Cash FlowN/A Price / Cash FlowN/A Book Value$4.38 per share Price / Book5.84Miscellaneous Outstanding Shares86,476,000Free Float82,438,000Market Cap$2.21 billion OptionableOptionable Beta0.19 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Steven L. Hoerter (Age 53)President, CEO & Director Comp: $1.24MMr. Thomas Patrick Kelly J.D. (Age 53)Executive VP, CFO & Treasurer Comp: $778.85kMr. Daniel C. Martin (Age 49)Senior VP & Chief Commercial Officer Comp: $711.42kDr. Matthew L. Sherman M.D. (Age 68)Executive VP & Chief Medical Officer Comp: $865.62kDr. Kevin Brodbeck Ph.D.Senior VP & Chief Technical OfficerDr. Dashyant Dhanak Ph.D. (Age 63)Executive VP & Chief Scientific Officer Jennifer LarsonSenior Vice President of Finance & Investor RelationsMr. Jeffrey M. Held J.D.Senior VP & General CounselMs. Lisa Amaya PriceSenior VP & Chief Human Resources OfficerMs. Jama Pitman (Age 44)Senior VP & Chief Development Officer More ExecutivesKey CompetitorsFive Prime TherapeuticsNASDAQ:FPRXSyndax PharmaceuticalsNASDAQ:SNDXXencorNASDAQ:XNCRALX OncologyNASDAQ:ALXOSeres TherapeuticsNASDAQ:MCRBView All CompetitorsInsiders & InstitutionsRedmile Group LLCBought 495,103 shares on 5/16/2024Ownership: 6.125%Jacobs Levy Equity Management Inc.Bought 47,936 shares on 5/16/2024Ownership: 0.546%California State Teachers Retirement SystemSold 2,581 shares on 5/16/2024Ownership: 0.044%Price T Rowe Associates Inc. MDBought 1,984 shares on 5/15/2024Ownership: 0.018%Lazard Asset Management LLCSold 539 shares on 5/15/2024Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions DCPH Stock Analysis - Frequently Asked Questions Should I buy or sell Deciphera Pharmaceuticals stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last twelve months. There are currently 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DCPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DCPH, but not buy additional shares or sell existing shares. View DCPH analyst ratings or view top-rated stocks. What is Deciphera Pharmaceuticals' stock price target for 2024? 10 Wall Street analysts have issued 1 year price targets for Deciphera Pharmaceuticals' stock. Their DCPH share price targets range from $16.00 to $30.00. On average, they expect the company's share price to reach $24.17 in the next twelve months. This suggests that the stock has a possible downside of 5.5%. View analysts price targets for DCPH or view top-rated stocks among Wall Street analysts. How have DCPH shares performed in 2024? Deciphera Pharmaceuticals' stock was trading at $16.13 at the beginning of 2024. Since then, DCPH shares have increased by 58.6% and is now trading at $25.59. View the best growth stocks for 2024 here. Are investors shorting Deciphera Pharmaceuticals? Deciphera Pharmaceuticals saw a decrease in short interest in the month of May. As of May 31st, there was short interest totaling 3,170,000 shares, a decrease of 19.1% from the May 15th total of 3,920,000 shares. Based on an average trading volume of 1,830,000 shares, the short-interest ratio is currently 1.7 days. Approximately 5.7% of the company's shares are short sold. View Deciphera Pharmaceuticals' Short Interest. When is Deciphera Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our DCPH earnings forecast. How were Deciphera Pharmaceuticals' earnings last quarter? Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) released its quarterly earnings results on Friday, May, 10th. The company reported ($0.52) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.03. The business earned $45 million during the quarter, compared to the consensus estimate of $45.99 million. Deciphera Pharmaceuticals had a negative net margin of 108.86% and a negative trailing twelve-month return on equity of 52.42%. What ETFs hold Deciphera Pharmaceuticals' stock? ETFs with the largest weight of Deciphera Pharmaceuticals (NASDAQ:DCPH) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA) and iShares Genomics Immunology and Healthcare ETF (IDNA).Global X Aging Population ETF (AGNG). What is Steve Hoerter's approval rating as Deciphera Pharmaceuticals' CEO? 3 employees have rated Deciphera Pharmaceuticals Chief Executive Officer Steve Hoerter on Glassdoor.com. Steve Hoerter has an approval rating of 100% among the company's employees. This puts Steve Hoerter in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Deciphera Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Vertex Pharmaceuticals (VRTX), Allena Pharmaceuticals (ALNA), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM) and Exelixis (EXEL). When did Deciphera Pharmaceuticals IPO? Deciphera Pharmaceuticals (DCPH) raised $101 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Nomura were co-managers. Who are Deciphera Pharmaceuticals' major shareholders? Deciphera Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Redmile Group LLC (6.12%), Vanguard Group Inc. (5.55%), Jacobs Levy Equity Management Inc. (0.55%), Essex Investment Management Co. LLC (0.35%), Swiss National Bank (0.09%) and GSA Capital Partners LLP (0.06%). Insiders that own company stock include Brightstar Associates Llc, Daniel C Martin, Daniel Lee Flynn, Dennis Leo Walsh, Franklin Stuart Friedman, Jama Pitman, Matthew L Sherman, Steven L Hoerter and Thomas Patrick Kelly. View institutional ownership trends. How do I buy shares of Deciphera Pharmaceuticals? Shares of DCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DCPH) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that...Porter & Company | SponsoredBiden out June 13; replacement chosen?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredBuy this small stock before coming AI Tidal WaveThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of ne...Chaikin Analytics | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Deciphera Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Deciphera Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.